Download PDF
intensiv 2015; 23(05): 267-270
DOI: 10.1055/s-0041-105107
CNE Schwerpunkt
Kardiologie
Georg Thieme Verlag KG Stuttgart · New York

Vorhofohr-Okkluder als Alternative zur Antikoagulation

Dieter Fischer
Further Information

Publication History

Publication Date:
04 September 2015 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die interventionelle Kardiologie entwickelte sich in den letzten Jahren erheblich weiter, insbesondere im Bereich der Interventionen struktureller Erkrankungen wie z. B. dem Aortenklappenersatz (TAVI), Verfahren zur Behandlung schwerer Mitralklappeninsuffizienzen, dem Verschluss von Vorhof- bzw. Kammerscheidewanddefekten und vielem mehr. Seit einigen Jahren werden in stark wachsender Anzahl auch interventionelle Vorhofohrverschlüsse bei Patienten mit Vorhofflimmern zur Schlaganfallprophylaxe vorgenommen. Wir stellen dieses Verfahren näher vor.

 

  • Literatur

  • 1 Fuster V et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114 (7) e257-e354
    CrossrefPubMedGoogle Scholar
  • 2 Camm AJ et al. 2012; focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33 (21) 2719-2747
    CrossrefPubMedGoogle Scholar
  • 3 Connolly SJ et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361 (12) 1139-1151
    CrossrefPubMedGoogle Scholar
  • 4 Patel MR et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365 (10) 883-891
    CrossrefPubMedGoogle Scholar
  • 5 Granger CB et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365 (11) 981-992
    CrossrefPubMedGoogle Scholar
  • 6 Giugliano RP et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369 (22) 2093-2104
    CrossrefPubMedGoogle Scholar
  • 7 Lip GY, Edwards SJ. Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis. Thromb Res 2006; 118 (3) 321-333
    CrossrefGoogle Scholar
  • 8 Gladstone DJ et al. Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated. Stroke 2009; 40 (1) 235-240
    CrossrefGoogle Scholar
  • 9 Ruff CT et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383 (9921) 955-962
    CrossrefPubMedGoogle Scholar
  • 10 Protheroe J et al. The impact of patients’ preferences on the treatment of atrial fibrillation: observational study of patient based decision analysis. BMJ 2000; 320 (7246) 1380-1384
    CrossrefGoogle Scholar
  • 11 Onalan O, Crystal E. Left atrial appendage exclusion for stroke prevention in patients with nonrheumatic atrial fibrillation. Stroke 2007; 38 (2 Suppl): 624-630
    CrossrefGoogle Scholar
  • 12 Cox JL, Ad N, Palazzo T. Impact of the maze procedure on the stroke rate in patients with atrial fibrillation. J Thorac Cardiovasc Surg 1999; 118 (5) 833-840
    CrossrefGoogle Scholar
  • 13 Kanderian AS et al. Success of surgical left atrial appendage closure: assessment by transesophageal echocardiography. J Am Coll Cardiol 2008; 52 (11) 924-999
    CrossrefPubMedGoogle Scholar
  • 14 Dawson AG, Asopa S, Dunning J. Should patients undergoing cardiac surgery with atrial fibrillation have left atrial appendage exclusion?. Interact Cardiovasc Thorac Surg 2010; 10 (2) 306-311
    CrossrefGoogle Scholar
  • 15 Ostermayer SH et al. Percutaneous left atrial appendage transcatheter occlusion (PLAATO system) to prevent stroke in high-risk patients with non-rheumatic atrial fibrillation: results from the international multi-center feasibility trials. J Am Coll Cardiol 2005; 46 (1) 9-14
    CrossrefGoogle Scholar
  • 16 Holmes DR et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet 2009; 374 (9689) 534-542
    CrossrefGoogle Scholar
  • 17 Reddy VY et al. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. JAMA 2014; 312 (19) 1988-1998
    CrossrefGoogle Scholar
  • 18 Holmes Jr. DR et al. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol 2014; 64 (1) 1-12
    CrossrefGoogle Scholar
  • 19 Park JW et al. Left atrial appendage closure with Amplatzer cardiac plug in atrial fibrillation: initial European experience. Catheter Cardiovasc Interv 2011; 77 (5) 700-706
    CrossrefGoogle Scholar